Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00456365 · ClinicalTrials.gov registry record · Phase 3
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 3 study of Polycystic Kidney, Autosomal Dominant, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT00456365 is a Phase 3 study of Polycystic Kidney, Autosomal Dominant that has completed, run by University of Colorado, Denver. The registered enrollment target is 110 participants, above the 50-participant average among 4 other Polycystic Kidney, Autosomal Dominant trials with a reported enrollment target (120% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00456365, a Phase 3 study of Polycystic Kidney, Autosomal Dominant, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether the medication pravastatin will ameliorate renal and cardiovascular disease over a 3-year period in children and young adults with autosomal dominant polycystic kidney disease (ADPKD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG pravastatin
Study Locations (1)
Colorado
- University of Colorado at Denver and Health Sciences Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2006-11 |
| Est. Completion | 2012-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00456365
The ClinicalTrials.gov registry entry for NCT00456365 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 50-participant average among 4 other Polycystic Kidney, Autosomal Dominant trials with a reported enrollment target (120% higher). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Polycystic Kidney, Autosomal Dominant appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00456365 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT00456365 about?
NCT00456365 is a clinical study titled "Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)". The purpose of this study is to determine whether the medication pravastatin will ameliorate renal and cardiovascular disease over a 3-year period in children and young adults with autosomal dominant polycystic kidney disease (ADPKD).
What is the current status of trial NCT00456365?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2006-11. Estimated completion is 2012-10.
What conditions does trial NCT00456365 study?
This clinical trial studies the following conditions: Polycystic Kidney, Autosomal Dominant.
What interventions are being tested in trial NCT00456365?
The interventions under investigation include: Placebo (DRUG), pravastatin (DRUG).
Who is sponsoring clinical trial NCT00456365?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00456365 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycystic Kidney, Autosomal Dominant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
ACTIVE NOT RECRUITING · Phase 2
-
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
COMPLETED · Phase 2
-
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
COMPLETED · NA
-
Effect of Venglustat in Patients With Renal Impairment
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.